

Oncology Oral Medications Enrollment Form



Fax Referral To: 207-899-0968
Address: 141 Preble St. Portland, ME 04101

Phone: 877-814-8447
NCPDP: 2008301

Six Simple Steps to Submitting a Referral

1 PATIENT INFORMATION (Complete or include demographic sheet)

Patient Name: _____
 Address: _____
 City, State, ZIP: _____

Preferred Contact Method: Phone Text Email
(to primary # provided below) (to cell # provided below) (to email provided below)
Note: Carrier charges may apply. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.

Primary Phone: _____ Home Cell Work
 Alternate Phone: _____ Home Cell Work
 DOB: _____ Gender: Male Female
 Email: _____
 Last Four of SSN: _____ Primary Language: _____

2 PRESCRIBER INFORMATION

Prescriber's Name: _____
 State License #: _____ NPI #: _____
 DEA #: _____

Group or Hospital: _____
 Address: _____
 City, State, ZIP: _____
 Phone: _____
 Fax: _____
 Contact Person: _____
 Contact's Phone: _____

3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: _____
 Ship to: Patient Office Other: _____

Diagnosis (ICD-10):
 Code: _____ Description: _____
 Code: _____ Description: _____

Patient Clinical Information:
 Allergies: _____
 Weight: _____ lbs/kg Height: _____ Inches/cm
 BSA: _____ m²

For additional ICD-10 information, please visit www.CVSSpecialty.com/ICD10

5 PRESCRIPTION INFORMATION

Medications:
 Revlimid REMS™ Program Physician Auth #: _____ Date: _____
 Pomalyst REMS™ Program Physician Auth #: _____ Date: _____
 Thalomid REMS™ Program Physician Auth #: _____ Date: _____

Diagnosis: MDS D46.9
 MM C90.00
 MCL C83.10

Pregnancy Category:
 Adult Female – Reproductive Potential Adult Female – NOT of Reproductive Potential Adult Male
 Female Child – Reproductive Potential Female Child – NOT of Reproductive Potential Male Child

- | | | | |
|---|--|---|---|
| <input type="checkbox"/> Afinitor® (everolimus) | <input type="checkbox"/> Idhifa® (enasidenib) | <input type="checkbox"/> Purixan® (mercaptopurine) | <input type="checkbox"/> Temodar® Capsules (temozolomide) |
| <input type="checkbox"/> Afinitor® Disperz (everolimus) | <input type="checkbox"/> Inlyta® (axitinib) | <input type="checkbox"/> Revlimid® (lenalidomide) | <input type="checkbox"/> Thalomid® (thalidomide) |
| <input type="checkbox"/> Alecensa® (alectinib) | <input type="checkbox"/> Iressa® (gefitinib) | <input type="checkbox"/> Rubraca™ (rucaparib) | <input type="checkbox"/> Tykerb® (lapatinib) |
| <input type="checkbox"/> Alunbrig™ (brigatinib) | <input type="checkbox"/> Jakafi® (ruxolitinib) | <input type="checkbox"/> Rydapt® (midostaurin) | <input type="checkbox"/> Verzenio™ (abemaciclib) |
| <input type="checkbox"/> Bosulif® (bosutinib) | <input type="checkbox"/> Kisqali® (ribociclib) | <input type="checkbox"/> Sprycel® (dasatinib) | <input type="checkbox"/> Votrient® (pazopanib) |
| <input type="checkbox"/> Cabometyx™ (cabozantinib) | <input type="checkbox"/> Lonsurf® (trifluridine & tipiracil) | <input type="checkbox"/> Stivarga® (regorafenib) | <input type="checkbox"/> Xalkori® (crizotinib) |
| <input type="checkbox"/> Cotellic™ (cobimetinib) | <input type="checkbox"/> Mekinist® (trametinib) | <input type="checkbox"/> Sutent® (sunitinib malate) | <input type="checkbox"/> Xeloda® (capecitabine) |
| <input type="checkbox"/> Erivedge® (vismodegib) | <input type="checkbox"/> Nerlynx™ (neratinib) | <input type="checkbox"/> Tafinlar® (dabrafenib) | <input type="checkbox"/> Xtandi® (enzalutamide) |
| <input type="checkbox"/> Erleada™ (apalutamide) | <input type="checkbox"/> Nexavar® (sorafenib) | <input type="checkbox"/> Tagrisso™ (osimertinib) | <input type="checkbox"/> Zelboraf® (vemurafenib) |
| <input type="checkbox"/> Farydak® (panobinostat) | <input type="checkbox"/> Ninlaro® (ixazomib) | <input type="checkbox"/> Tarceva® (erlotinib HCl) | <input type="checkbox"/> Zolanza® (vorinostat) |
| <input type="checkbox"/> Gleevec® (imatinib mesylate) | <input type="checkbox"/> Odomzo® (sonidegib) | <input type="checkbox"/> Targretin® Capsules (bexarotene) | <input type="checkbox"/> Zykadia™ (ceritinib) |
| <input type="checkbox"/> Hycamtin® Capsules (topotecan) | <input type="checkbox"/> Pomalyst® (pomalidomide) | <input type="checkbox"/> Tassigna® (nilotinib) | <input type="checkbox"/> Zytiga® (abiraterone) |
| <input type="checkbox"/> Ibrance® (palbociclib) | <input type="checkbox"/> Other: _____ | | |

Rx 1	Drug Name/Strength: Quantity:	Sig/Directions: Refills:
Rx 2	Drug Name/Strength: Quantity:	Sig/Directions: Refills:
Rx 3	<input type="checkbox"/> Dexamethasone <input type="checkbox"/> Exemastane <input type="checkbox"/> Letrozole <input type="checkbox"/> Prednisone Sig/Directions:	Strength: Quantity: Refills:

Patient is interested in patient support programs

STAMP SIGNATURE NOT ALLOWED

Ancillary supplies and kits provided as needed for administration

PHYSICIAN SIGNATURE REQUIRED

PRODUCT SUBSTITUTION PERMITTED (Date) _____
 DISPENSE AS WRITTEN (Date) _____

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty®.

75-35450B 030718